 Safety outcomes will be assessed by physical examination including neurological examination, clinical laboratory tests and 12-lead electrocardiogram ECG at screening and at selected subsequent scheduled visits. Vital signs, including weight, concomitant medications, and adverse events will be monitored regularly throughout the trial. Changes in anti-parkinsonian medications will be permitted at the Investigators discretion. 